Ribatti D, Urbinati C, Nico B, Rusnati M, Roncali L, Presta M
Institute of Human Anatomy, Histology and Embryology, School of Medicine, University of Bari, Italy.
Dev Biol. 1995 Jul;170(1):39-49. doi: 10.1006/dbio.1995.1193.
Chorioallantoic membrane (CAM) and chorioallantoic fluid (CAF) of the chick embryo were studied for the presence of immunoreactive and biologically active basic fibroblast growth factor (bFGF) from Day 6 to Day 18 of incubation. An immunoreactive M(r) 16,000 bFGF-like molecule was detected both in CAM and in CAF. This molecule was identified as bFGF on the basis of its molecular weight, its affinity for heparin, and its capacity to induce plasminogen activator production in cultured endothelial GM 7373 cells. The levels of biologically active and immunoreactive bFGF vary in CAM and CAF during embryonic development, maximal concentrations being observed between Days 10 and 14 of incubation. At all time points investigated, absolute concentrations of bFGF were significantly higher in CAM (ranging from 25 to 183 ng/g of wet tissue) than in CAF (ranging from 0.2 to 4 ng/ml). In a parallel series of experiments performed at Day 8 and evaluated at Day 12 of chick embryo development, human recombinant bFGF and neutralizing anti-bFGF antibody were investigated for their capacity to affect the vasoproliferative processes of the CAM. The two molecules either were applied onto the surface of the CAM or were injected into the allantoic sac. When bFGF or anti-bFGF antibodies were absorbed on methylcellulose discs and applied on the top of the CAM, they exerted a strong angiogenic or anti-angiogenic effect, respectively. On the contrary, when bFGF or the corresponding neutralizing antibody was injected into the allantoic sac, no modifications of the vasoproliferative processes of the CAM were observed at either the macroscopic or the microscopic level. These results provide evidence indicating that endogenous bFGF has a rate-limiting role in the vascularization of the CAM during chick embryogenesis. bFGF located within the CAM, rather than that present in the CAF, appears to be involved in this developmental process.
在鸡胚孵化的第6天至第18天,研究了鸡胚的绒毛尿囊膜(CAM)和绒毛尿囊液(CAF)中免疫反应性和生物活性碱性成纤维细胞生长因子(bFGF)的存在情况。在CAM和CAF中均检测到一种免疫反应性的分子量为16,000的bFGF样分子。基于其分子量、对肝素的亲和力以及在培养的内皮GM 7373细胞中诱导纤溶酶原激活物产生的能力,该分子被鉴定为bFGF。在胚胎发育过程中,CAM和CAF中生物活性和免疫反应性bFGF的水平有所变化,在孵化的第10天至第14天观察到最高浓度。在所有研究的时间点,CAM中bFGF的绝对浓度(范围为25至183 ng/g湿组织)显著高于CAF(范围为0.2至4 ng/ml)。在鸡胚发育第8天进行的一系列平行实验,并在第12天进行评估,研究了人重组bFGF和中和抗bFGF抗体影响CAM血管增生过程的能力。这两种分子要么应用于CAM表面,要么注入尿囊。当bFGF或抗bFGF抗体吸附在甲基纤维素圆盘上并应用于CAM顶部时,它们分别产生强烈的血管生成或抗血管生成作用。相反,当bFGF或相应的中和抗体注入尿囊时,在宏观或微观水平上均未观察到CAM血管增生过程的改变。这些结果提供了证据,表明内源性bFGF在鸡胚发生过程中对CAM血管化具有限速作用。似乎是位于CAM内而非CAF中的bFGF参与了这一发育过程。